Trials / Completed
CompletedNCT04328571
Effects of Enzymatic Digestion and Probiotic on Oleuropein Bioavailability
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Société des Produits Nestlé (SPN) · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a 3-arms randomized-controlled, parallel group, single center, double-blind study investigating the bioavailability of olive oil extract (OLE) in two different OLE formulations (enzymatically treated and co-administered with a probiotic) compared to original OLE formulation in healthy adult subjects.
Detailed description
Male or female healthy adults between 25 and 65 years of age will be randomized into one of the 3 following groups to receive: 1. Capsule of OLE + 1 stick of maltodextrin 2. Capsule of OLE enzymatically treated + 1 stick of maltodextrin 3. Capsule OLE + 1 stick of probiotic 52 subjects will be randomized to achieve 15 subjects per group to complete the trial. The study will involve 3 phases: 1. PK1 (all subjects will receive one capsule of OLE in the morning and blood samples will be collected at different timepoints for 24h) followed by a washout period of 1 day 2. 3 weeks intervention (subjects will receive the product thy have benn assigned to) followed by a wash-out period of 3 days 3. PK2 period (subjects will receive one capsule the product thy have benn assigned to
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | OLE enzymatically treated | OLE (Olive leaf extract ) enzymatically treated + maltodextrin |
| DIETARY_SUPPLEMENT | OLE + probiotic | OLE (Olive leaf extract) co-administered with probiotic |
| DIETARY_SUPPLEMENT | OLE | OLE (Olive leaf extract) + maltodextrin |
Timeline
- Start date
- 2020-02-10
- Primary completion
- 2021-05-15
- Completion
- 2021-09-15
- First posted
- 2020-03-31
- Last updated
- 2021-10-01
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04328571. Inclusion in this directory is not an endorsement.